Results 231 to 240 of about 9,766,746 (345)

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy [PDF]

open access: green, 2010
Elena Pegoraro   +16 more
openalex   +1 more source

Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells

open access: yesAdvanced Functional Materials, EarlyView.
CRISPR machinery in diverse molecular formats (DNA, RNA, and ribonucleic protein) is complexed into nanoparticles with the cell‐friendly arginine‐alanine‐leucine‐alanine (RALA) cell‐penetrating peptide. Nanoparticles are delivered to primary mesenchymal stem cells ex vivo or locally in vivo to facilitate multimodal CRISPR gene editing. This RALA‐CRISPR
Joshua P. Graham   +9 more
wiley   +1 more source

Differential Compartmentalization of Enzymatic Reactions for Lactate Signaling Across Protocells

open access: yesAdvanced Functional Materials, EarlyView.
Two populations of protocells consisting of giant unilamellar vesicles containing active species and distinct artificial organelles are competent of collective behavior by mimicking production, intercellular communication, and detection of the bioinspired signal molecule lactate. Enzymatic cascade reactions within artificial organelles demonstrate that
Arianna Balestri   +4 more
wiley   +1 more source

675 Spinal Muscular Atrophy: Two Cases of Rapidly Progressive Disease [PDF]

open access: bronze, 2010
J Extreia   +5 more
openalex   +1 more source

Cholesterol in mRNA‐Lipid Nanoparticles can be Replaced with the Synthetic Mycobacterial Monomycoloyl Glycerol Analogue MMG‐1

open access: yesAdvanced Functional Materials, EarlyView.
This study demonstrates that cholesterol in messenger RNA‐lipid nanoparticles (mRNA‐LNPs) can be completely replaced with an immunopotentiating lipid, i.e., a synthetic analogue of the C‐type lectin receptor agonist monomycoloyl glycerol (MMG‐1), without compromising physicochemical properties, in vivo transfection efficiency, and immunogenicity of the
Abhijeet G. Lokras   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy